ee

Registreeru
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele.
Kodu・Aktsiate loetelu・AstraZeneca PLC
Search

AstraZeneca PLC

Suletud

Sektor Tervishoid

11,844 -0.72

Osta

Hinna uuendus 22. okt 2024, 15:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11768

Max

11930

Põhinäitajad

By Trading Economics

Sissetulek

-252M

1.9B

Müük

258M

13B

P/E

Sektori keskmine

38.58

112.16

Aktsiakasum

1.98

Kasumimarginaal

14.894

EBITDA

-349M

4.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+14.68 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2024

Turustatistika

By TradingEconomics

Turukapital

992M

187B

Eelmine avamishind

11844.72

Eelmine sulgemishind

11844

Uudiste sentiment

By Acuity

30%

70%

74 / 366 Pingereas Healthcare

AstraZeneca PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. sept 2024, 09:29 UTC

Suurimad hinnamuutused turgudel

AstraZeneca Shares Slump After Cancer Drug Misses Key Target

DJ

Loe

25. juuli 2024, 09:17 UTC

Tulu

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

DJ

Loe

25. juuli 2024, 06:48 UTC

Tulu

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

DJ

Loe

12. sept 2024, 17:01 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

DJ

Loe

12. sept 2024, 11:00 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

DJ

Loe

10. sept 2024, 13:08 UTC

Market Talk

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

DJ

Loe

9. sept 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

DJ

Loe

5. sept 2024, 13:00 UTC

Peamised uudised

China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ

DJ

Loe

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

DJ

Loe

25. juuli 2024, 13:20 UTC

Tulu

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

DJ

Loe

25. juuli 2024, 09:21 UTC

Market Talk
Tulu

AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk

DJ

Loe

25. juuli 2024, 07:05 UTC

Market Talk
Tulu

AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk

DJ

Loe

25. juuli 2024, 06:06 UTC

Tulu

AstraZeneca Increased Interim Dividend by 7c to $1.00

DJ

Loe

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Loe

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Loe

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Loe

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Loe

25. juuli 2024, 06:03 UTC

Tulu

AstraZeneca Raises 2024 View

DJ

Loe

25. juuli 2024, 06:02 UTC

Tulu

AstraZeneca 2Q Revenue Consensus Was $12.7B

DJ

Loe

25. juuli 2024, 06:02 UTC

Tulu

AstraZeneca 2Q Core EPS Consensus Was $1.95

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Adj EPS $1.98

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Pretax Pft $2.4B

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Rev $12.94B

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Oper Pft $2.75B

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Net Pft $1.93B

DJ

Loe

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q EPS $1.24

DJ

Loe

15. juuli 2024, 06:04 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Loe

15. juuli 2024, 06:04 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Loe

15. juuli 2024, 06:02 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing

DJ

Loe

15. juuli 2024, 06:02 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B

DJ

Loe

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

14.68% tõus

12 kuu keskmine prognoos

Keskmine 13,681.16 GBX  14.68%

Kõrge 20,000 GBX

Madal 10,500 GBX

Põhineb 16 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

10

Osta

3

Hoia

3

Müü

Põhineb 16 analüütiku instrumendi AstraZeneca PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

74 / 366 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.